NEW BREAST CANCER DRUGS
ANCHOR LEAD: A NEW TYPE OF DRUG TO BATTLE BREAST CANCER IS SHOWING PROMISING RESULTS. ELIZABETH TRACEY REPORTS
PolyADP ribose polymerase is abbreviated, even by the experts, as PARP. Turns out PARP is the target for a new class of drugs designed to fight one of the most difficult to treat types of breast cancer. Bill Nelson, director of the Kimmel Cancer Center at Johns Hopkins, describes study findings presented at the recent American Society for Clinical Oncology meeting.
NELSON: This is one of the early reports with an experience with one of these drugs treating a type of breast cancer that at the moment is the hardest to treat, so called triple negative breast cancer, won’t respond to hormones, doesn’t respond to Herceptin, doesn’t respond particularly well to anything. A trial done in women with this type of breast cancer using these PARP inhibitors, not yet approved and available throughout the country, so one of the first trials, showed a very provocative benefit from much of anything, that’s where all the excitement is. :29
Nelson predicts this class of drugs will be on the fast track for FDA approval. At Johns Hopkins, I’m Elizabeth Tracey.